MRNA President Hoge sells 53,336 shares at $48.40; stock down 10.4% in 30 days, company lost $1.3B in last year.
Stephen Hoge, President of Moderna, sold 53,336 shares (53.3K shares) on 2026-05-15 at $48.40, reducing his holdings by 3.5% to 1.48M shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-13 and therefore represents a scheduled trade rather than a discretionary decision. The sale occurs against a backdrop of negative recent price momentum, with MRNA down 10.4% over the prior 30 days and trading 19.2% below its 52-week high of $59.55. More significantly, Moderna's fundamentals show deterioration: the company reported a net loss of $1.3B in its most recent full year and annual revenue declined 39.9% year-over-year, reflecting the sharp contraction in pandemic-related demand. His prior five trades at MRNA show mixed outcomes, including a notable 90-day loss of 51.9% following a July 2024 sale, but this current transaction is scheduled under a pre-arranged plan rather than a discretionary market response.